Premium
FGF6 mediated expansion of a resident subset of cells with SP phenotype in the C2C12 myogenic line
Author(s) -
Israeli David,
Benchaouir Rachid,
Ziaei Simindokht,
Rameau Philippe,
Gruszczynski Carole,
Peltekian Elise,
Danos Olivier,
Garcia Luis
Publication year - 2004
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.20088
Subject(s) - myod , myf5 , myogenesis , myogenin , biology , ectopic expression , c2c12 , microbiology and biotechnology , myogenic regulatory factors , progenitor cell , myod protein , myocyte , cell culture , stem cell , genetics
Fibroblast growth factor 6 (FGF6) is selectively expressed during muscle development and regeneration. We examined its effect on muscle precursor cells (mpc) by forcing stable FGF6 expression in C2C12 cells in vitro. FGF6 produced in genetically engineered mpc was active, inducing strong morphological changes, altering cell adhesion and compromising their ability to differentiate into myotubes. Expression of MyoD and myogenin, but not of Myf5, was abrogated in FGF6 engineered mpc. These effects were reversed by FGF inhibitors. Ectopic expression of MyoD also restored fiber formation indicating that FGF6 interferes with the myogenic differentiation pathway upstream of MyoD. We also report that in the presence of FGF6, the minor (0.5–2%) subpopulation of cells actively excluding Hoechst 33342 in a verapamil‐dependent manner (SP phenotype) was increased to 15–20% and the expression of the mdr1a gene (but not mdr1b ) was upregulated by 400‐fold. Our data establish a previously undescribed link between FGF6—a muscle specific growth factor—and a multidrug resistance gene expressed in stem cells, and suggest a role for FGF6 in the maintenance of a reserve pool of progenitor cells in the skeletal muscle. © 2004 Wiley‐Liss, Inc.